Research programme: cancer therapeutics - Bluebird Bio/Celgene

Drug Profile

Research programme: cancer therapeutics - Bluebird Bio/Celgene

Alternative Names: Anti-BCMA CAR T-cells

Latest Information Update: 08 May 2016

Price : $50

At a glance

  • Originator bluebird bio
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies
  • Mechanism of Action B-cell maturation antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma

Most Recent Events

  • 16 Apr 2016 Pharmacodynamics data from a preclinical study presented at the 107th Annual meeting of the American Association of Cancer Research (AACR-2016)
  • 06 Dec 2015 Pharmacodynamics data from preclinical trials in Multiple myeloma released by Bluebird Bio (9188610; 9187079)
  • 03 Mar 2015 Preclinical trials in Multiple myeloma (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top